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Abstract
Background: Moderate to severe psoriasis is a systemic inflammatory disease associated with insulin resistance,
obesity and type 2 diabetes (T2DM). Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycaemia
and has a marketing authorisation for the treatment of T2DM. Non-immunosuppressive therapies that are effective
for psoriasis and its associated comorbidities would be a significant advance in the treatment of this chronic
disease.
Methods/Design: This is a single centre, 39-week, prospective, randomised, open label, clinical trial of oral sitagliptin
(Januvia®) in psoriasis patients who are due to undergo a course of narrow-band ultraviolet-B (NB-UVB) phototherapy.
We plan to enrol 120 participants and allocate participants on a random and 1:1 basis to receive sitagliptin 100 mg
daily for 24 weeks combined with NB-UVB or NB-UVB monotherapy. Participants will be followed up for 12 weeks
after sitagliptin therapy is discontinued. The primary endpoint is the change in Psoriasis Area and Severity Index
(PASI) 24 weeks after treatment initiation. Secondary endpoints include cumulative NB-UVB dose, number of NB-UVB
treatments required to clear psoriasis, proportions of participants who achieve PASI-50 (50 % reduction in PASI from
baseline), PASI-75, PASI-90 and the proportion of participants who relapse in each group. We will also analyse changes
in cardiovascular disease risk factors, serum cytokine and hormone levels and peripheral blood mononuclear
expression of immune proteins at 24 and 36 weeks. A subgroup of participants will have skin biopsies taken and
analysed for skin levels and expression of immune cells, receptors, hormones and immune proteins. The genetic or
epigenetic profile that predicts best response to DPP-4 inhibitor therapy will be analysed. The safety endpoints include
the rate and severity of adverse events.
Discussion: This is the first randomised clinical trial assessing dipeptidyl peptidase-4 inhibition therapy in psoriasis. We
hypothesise that sitagliptin therapy in combination with NB-UVB improves psoriasis severity compared to NB-UVB
monotherapy.
Trial registration: ClinicalTrials.gov Identifier NCT02347501 (Date of registration: 27 January 2015).
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Background
Psoriasis is a common immune-mediated skin disease af-
fecting 1.3–2.2 % of the UK population [1] with chronic
plaque psoriasis being the most common (90 %) form [2].
The majority of patients have mild psoriasis although
around 20–30 % of patients have more severe involvement
that warrants consideration of systemic therapy [3].
Treatment options for severe psoriasis include systemic
immunosuppressant therapies such as methotrexate and
fumaric acid esters which are effective but associated with
potential toxicities. Biologic therapies have revolutionised
the management of psoriasis but are expensive and are
immunosuppressive. Psoriasis has a significant impact on
quality of life and those patients with severe disease have
an approximately 4-year reduction in life span [4]. Moder-
ate to severe psoriasis is associated with smoking, alcohol
excess, obesity and type 2 diabetes (T2DM) [5]. These co-
morbidities likely contribute to increased cardiovascular
risk and premature mortality [6] as does the systemic
inflammation associated with psoriasis [7]. An effective
treatment for psoriasis that is non-immunosuppressive
and treats comorbidities such as diabetes would, therefore,
be very welcome.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) in-
hibitor that has a marketing authorisation for T2DM.
Sitagliptin has placebo-like tolerability and a good
safety profile. Two case reports have shown that sita-
gliptin improved psoriasis severity [8, 9]. Dipeptidyl
peptidase-4 is expressed on keratinocytes and its activ-
ity is upregulated in psoriasis [10, 11]. The main site
of DPP-4 activity is CD26. CD26 is a marker of T cell
activation and is a key molecule in the pathogenesis of
autoimmune diseases [12]. Agents used to treat psor-
iasis commonly target the underlying inflammation
[13, 14]. C-reactive protein (CRP) is a sensitive, sys-
temic marker of inflammation [15]. In people with
T2DM DPP-4 inhibitor therapy decreases CRP con-
centrations [16–22]. Serum CRP concentrations correlate
with psoriasis severity and interventions that decrease
the CRP concentration may decrease also psoriasis
severity [23–25].
We have shown previously, in psoriasis patients
without T2DM (both lean and obese), that homeosta-
sis model assessment of insulin resistance (HOMA-IR)
values correlate with those of the Psoriasis Area and
Severity Index (PASI, a measure of psoriasis severity:
r = 0.49, p < 0.001) [26].
Medications that improve insulin action may also de-
crease systemic inflammation and improve psoriasis
[27]. This study aims to assess the efficacy and safety of
sitagliptin, a DPP-4 inhibitor, in patients with psoriasis
without diabetes undergoing narrow-band ultraviolet-B
(NB-UVB) phototherapy. We hypothesise that sitagliptin
therapy improves psoriasis severity.
Methods/Design
Study design and study organisation
This will be a single centre, 39-week, prospective, rando-
mised, open label, clinical trial of oral sitagliptin tablets
(Januvia®) in psoriasis patients who are due to undergo a
course of NB-UVB phototherapy. We plan to enrol 120
research participants in total. Participants will be allocated
at random to receive either (a) 24 weeks of sitagliptin
(Januvia®, 100 mg daily, or 50 mg daily for participants
with moderate kidney disease) with NB-UVB photother-
apy; or (b) NB-UVB phototherapy without any additional
treatment. The primary outcome measure is the change
in the psoriasis area and severity index (ΔPASI) during
24 weeks of treatment. This parameter, along with sec-
ondary outcome measures, will be compared between
the two groups. This study has been approved by the
St Vincent’s University Hospital Ethics and Medical
Research Committee and by the Health Products
Regulatory Authority of Ireland.
This study will be carried out in compliance with the
study protocol and in accordance with the sponsor/con-
tract research organisations’ standard operating proce-
dures. These are designed to ensure adherence to Good
Clinical Practice (GCP) guidelines, as described in the
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use Harmonised Tripartite Guidelines for Good
Clinical Practice, 1996.
Trial registration
Ethical approval number: DPIP-2012-02
Date of approval: 19 June 2013
ClinicalTrials.gov Identifier: NCT02347501
EudraCT: 2012-005483-10
Data handling
All data will be stored securely. Details of outcome mea-
sures and adverse events will be documented in hospital
healthcare records, in individual research participant case
report forms and in an encrypted electronic database.
The study investigators will adhere to hospital proto-
cols pertaining to healthcare record use and storage. To
protect the research participant’s identity, a unique iden-
tification code will be assigned by the investigator, or
authorised designee, to each study participant and used
in lieu of the participant’s name when the investigator
reports adverse events and/or other study-related data
are reported.
Participants
Potentially eligible research participants will be identified
through use of a patient database and through review of
healthcare records in St Vincent’s University Hospital.
Potentially eligible research participants will be recruited
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in one of two ways by one of the study investigators or
by a suitably qualified designee. One of these two ways
will be during a clinic visit and the other will be by mail-
ing a letter of invitation.
Psoriasis patients attending this centre who have a
PASI greater than 7, and who are due to undergo NB-
UVB phototherapy, will be considered potentially eli-
gible research participants and will be invited to attend
for a screening visit. Informed consent will be obtained
from every participant in the trial. The PASI will be
measured at every visit by a senior clinician, or suitably
qualified designee. The PASI assessor will be blinded to
the participant’s randomisation group. After a 3-week
period, where research participants will not receive the
investigational medicinal product, those research
participants who meet all of the inclusion criteria and
do not fall under any of the exclusion criteria (Table 1)
will be allocated randomly, after stratification by glycated
haemoglobin (HbA1c) level (HbA1c <38 mmol/mol or
≥38 mmol/mol), body mass index level (BMI <30 kg/m2
or ≥30 kg/m2) and previous response to NB-UVB
(achieved remission within 25 exposures during most
recent course of NB-UVB or not), either to arm A or to
arm B. Those who have not been exposed previously to
NB-UVB will be placed in the ‘did not achieve remission
within 25 exposures’ group.
In order to achieve this we have prepared eight ran-
domisation lists using a web-based random generator
programme (http://www.randomization.com). For each
participant the investigator, or authorised designee,
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Patients who have a diagnosis of generalised chronic plaque
and/or guttate psoriasis
1. Patients with photosensitive disorders
2. Male and female patients aged between 18 and 75 years inclusive 2. Patients with diabetes mellitus
3. Patients with a PASI of 7 or greater at screening or baseline
despite use of topical therapies
3. Patients who are receiving medications that can cause photosensitivity
4. Patients who are due to undergo NB-UVB light therapy 4. Patient who are receiving GLP-1 analogue therapy
5. Patients who have not required systemic psoriasis therapy
during the past 8 weeks
5. Patients who have conditions that could be made worse by phototherapy
(cataracts, epilepsy, etc.)
6. Patients who are unlikely to require systemic therapy for the
duration of clinical trial involvement
6. Patients with allergy or hypersensitivity to Januvia®
7. Patients who have a negative pregnancy test at screening
(women of child-bearing potential only)
7. Patients with any of the following conditions:
severe kidney disease (estimated glomerular filtration rate of less than
30 ml/min/1.73 m2)
severe heart disease (left ventricular ejection fraction less than 35 %)
severe liver disease (alanine aminotransferase greater than 150 IU/L)
severe lung disease (forced expiratory volume in 1 second or a forced
vital capacity that is known to be less than 50 % of that estimated for a
person of that age and gender)
8. Patients who are willing to sign voluntarily a statement of
informed consent to participate in the study
8. Patients who have received NB-UVB light recently (within 8 weeks)
9. Patients who are receiving currently or have received systemic therapy for
psoriasis recently (within 8 weeks)
10. Patients who have any other contraindications to Januvia® as stated in its
Summary of Product Characteristics
11. Female patients of child-bearing potential who are pregnant, breastfeeding,
or unwilling to practice an acceptable barrier and/or hormonal method of
contraception during participation in the study – abstinence will be permitted
only if it is in keeping with a person’s lifestyle
12. Patients with any clinically significant chronic disease that might, in the
opinion of the investigator, interfere with the evaluations or preclude
completion of the trial
13. Patients with a current or recent (within the past 4 weeks) acute serious illness,
acute psychiatric illness or severe uncontrolled/unstable illness
14. Patients who have been randomised into this study previously
15. Patients who are participating in another clinical trial concurrently
16. Patients who are participating in another clinical trial during the 12 weeks
prior to study entry (i.e. screening visit)
GLP-1 glucagon-like peptide-1 analogue, NB-UVB narrow-band ultraviolet-B phototherapy, PASI psoriasis area and severity index
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will chose the appropriate list and will add the par-
ticipant’s identifier to the list in chronological order.
This list will be thereby used to determine the study
treatment which the participant will receive. Random
allocation will occur at visit 2 (baseline visit) once
all screening procedures required at visit 1 (screen-
ing visit) have been completed, once it has been
confirmed that the participant satisfies all inclusion
and exclusion criteria and once the participant com-
pletes the 3-week run-in period. Identification num-
bers will be assigned chronologically in consecutive,
ascending order.
Study treatments
Research participants allocated to arm A will receive a
26-week supply of Januvia® tablets (DPP-4 inhibitor) and
will be instructed to ingest orally one 100 mg tablet once
daily (or 50 mg once daily for participants with moder-
ate kidney disease) for 24 weeks (Fig. 1). Research partic-
ipants allocated to arm B will receive no treatment
(aside from usual medications and phototherapy). Both
the research participants and the investigators will be
aware of the trial arm to which the research participant
has been allocated randomly (open-label study).
All research participants will undergo NB-UVB
phototherapy during the initial portion of study par-
ticipation. This protocol involves whole-body NB-UVB
using a Waldmann UV5001 cabinet incorporating 40
100-watt Philips TL-01 fluorescent lamps (emitting
within the wavelength range of 311 nm to 313 nm) on
Mondays, Wednesdays and Fridays. Doses of NB-UVB
are adjusted according to the minimal erythema dose
(MED) and according to erythemal response to ther-
apy [28]. The MED is established by exposing eight
1.5 × 1.5 cm sites of unaffected skin of the upper back
to NB-UVB at various doses (50, 70, 100, 140, 200,
280, 390, 550, 770 and 1080 mJ/cm2) from a bank of
four TL-01 fluorescent tubes. The MED is defined as
the dose that causes barely perceptible erythema
24 hours after irradiation. The first dose is 70 % of the
MED and incremental increases are made at each visit
to a maximum dose of 3833 mJ/cm2. Patients are treated
until psoriasis clears or until they have received 40
exposures. All psoriasis patients wear protective UV gog-
gles and the men wear genital protection. Irradiance is
measured each month using an IL1400A radiometer and
SEL240/UVB-1/TD detector head that is calibrated annu-
ally against a reference standard.
Research participants are prohibited from using sys-
temic psoriasis therapy for the duration of their trial in-
volvement. Any other medications that are considered
necessary for the participant’s welfare and will not inter-
fere with the study medication will be given at the dis-
cretion of the investigator.
Safety
Comprehensive assessments of any apparent toxicity ex-
perienced by the research participant will be performed
throughout the course of the study from the time of par-
ticipant’s signature of informed consent. The safety of
the investigational medicinal products will be assessed
through the recording, reporting and analysing of base-
line medical conditions, adverse events, vital signs and
laboratory tests (full blood count, renal and liver blood
tests). Information about all serious adverse events
(SAEs) will be collected and recorded on the SAE Report
Form. Each SAE must be reported by the investigator, or
an authorised designee, to the sponsor within 24 hours
of learning of its occurrence.
Endpoints
Efficacy and safety measures will be performed accord-
ing to a schedule of assessments (Table 2).
The primary efficacy endpoint is the change in the
PASI (ΔPASI) after 24 weeks.
The secondary endpoints will include the:
1. ΔPASI after 36 weeks
2. Change in validated quality of life scores
(Dermatology Life Quality Index (DLQI), EuroQol 5
item questionnaire (EQ-5D), Hospital anxiety and
Depression Scale (HADS), and Stanford Health
Figure 1 Depiction of the flow of research participants through each stage of the study: randomisation of research participants to one of two
study arms, stages of no treatment and of treatment, and the medications that will be received by participants at each stage of the study
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Assessment Questionnaire 8-Item Disability Scale
(HAQ-8) after 24 and 36 weeks
3. NB-UVB light dosage and exposure number at
36 weeks
4. Proportion of patients who achieve a greater than
50 % reduction in PASI from baseline (PASI-50) by
36 weeks
5. Proportion of participants who achieve PASI-75 and
PASI-90 by 36 weeks
6. Proportion of participants who relapse (PASI greater
than 50 % of baseline value) by 36 weeks
7. Times taken to achieve PASI-50, PASI-75, PASI-90
and relapse
8. Changes in levels of cardiovascular disease risk
factors (blood pressure, glycaemic measures lipid
fractions, weight, etc.) after 24 and 36 weeks
9. Changes in serum concentrations of cytokines and
hormones after 24 and 36 weeks
10. Changes in peripheral blood mononuclear cell
expression of immune proteins (interleukin (IL)-6,
tumour necrosis factor alpha (TNFα), IL-10, IL-17,
interferon gamma, toll-like receptor 4, toll-like receptor
2, c-Jun N-terminal protein kinase 1, monocyte
chemoattractant protein-1, etc.) after 24 and
36 weeks
The tertiary efficacy endpoints, which will be deter-
mined only in a subgroup of willing clinical trial partici-
pants, are the:
1. Changes in skin levels and expression of cells,
hormones, receptors, enzymes and immune proteins
after 24 weeks; and
2. Genetic, and/or epigenetic, profile that predicts best
response to phototherapy and to DPP-4 inhibitor
therapy
Table 2 Schedule of assessments
Screening visit
(week 3)
Baseline visit
(day 0)
First treatment
visit (week
3 ± 7 days)
Second treatment
visit (week
6 ± 7 days)
Third
treatment
visit (week
12 ± 7 days)
Fourth
treatment
visit (week
24 ± 7 days)
First
follow-up
visit (week
30 ± 7 days))
End of study
visit (week
36 ± 7 days)
Early
withdrawal
visit
Visit number 1 2 3 4 5 6 7 8
Informed consent X
Inclusion/exclusion
criteria
X
Demographic
data
X
Medical history X
Quality of life
assessments
X X X X X X X X
Concomitant
medication
X X X X X X X X X
Height X
Weight X X X X X X X X X
Blood pressure
and heart rate
X X X X X X X X X
PASI assessment X X X X X X X X X
Blood samplesb X X X X X X X X X
Urinary pregnancy
test (women of
child-bearing
potential only)
X X X X
Adverse event
assessment
X X X X X X X X
IMP dispensing
(arm A)
X
IMP accountability
return and
compliance check
X X X X Xa
aif applicable
bsafety and efficacy variables
IMP Investigational Medicinal Product, PASI Psorasis Area and Severity Index
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The safety endpoints will include:
1. Full blood count
2. Renal and liver blood tests
3. Skin reactions (erythema, pruritus, stinging and
lesional blistering)
4. Reactivation of herpes simplex infection
5. Other adverse events
Statistical methods and sample size
Demographic and baseline clinical data will be sum-
marised using descriptive statistics according to treatment
group. The primary and secondary efficacy variables and
the safety variables will be summarised using descriptive
statistics according to treatment group.
Data from research participants who are not allocated
to either arm of the study and who do not receive a sup-
ply of investigational medicinal product will be excluded
from statistical analyses.
The analysis of the data will be based on an intention-
to-treat approach. T tests (or the appropriate alternative
for non-parametric data), using two-sided tests, will be
used to determine whether significant differences be-
tween the sets of data exist (SPSS version 20.0, IBM,
Armonk, NY, USA). The independent samples T test will
be used to assess for differences between the effects of
the test product (Januvia®) compared to the effects of no
additional treatment. Chi-square analyses will be used to
test for significant differences in categorical variables be-
tween the sets of data obtained. Missing data will be
dealt with using last observation carried forward.
Subgroup analyses will be performed on those research
participants who:
1. Complete the visit 6 assessment
2. Have severe psoriasis
3. Have non-severe psoriasis
4. Are male
5. Are female
6. Are obese
7. Are older than 45 years
We plan to enrol 120 research participants in total.
Kleinpenning et al. have determined previously the ef-
fect of two different NB-UVB phototherapy regimens on
the decrease in PASI 3 months after completion of a
course of NB-UVB phototherapy [29]. Three months
after cessation of NB-UVB light therapy the decrease in
the PASI in those receiving an high-dose regimen was
5.93 ± 4.1 compared to baseline. This decrease in PASI
was significantly less in the group receiving a low-dose
regimen (4.14 ± 2.96, p < 0.05).
Based on these data, and assuming a 20 % dropout
rate, we have calculated that we will require 60 research
participants (in each randomisation arm) to detect a
greater than 33 % difference in the ΔPASI with 80 %
power and a 5 % significance level.
Quality control of the study
A quality assurance audit may be conducted by the
sponsor or its agent at any time during, or shortly after,
the study. The investigator will permit an independent
audit by an auditor mandated by the sponsor, after rea-
sonable notice. The purpose of an audit is to confirm
that the study is conducted as per protocol, Good Clin-
ical Practice and applicable regulatory requirements, that
the rights and well-being of the patients enrolled have
been protected, and that the data relevant for the evalu-
ation of the investigational medicinal product have been
captured, processed and reported in compliance with the
planned arrangements. The investigator will permit dir-
ect access to all study documents, drug accountability
records, medical records and source data.
A future report will follow the Consolidated Standards
of Reporting Trials (CONSORT) statement.
Discussion
Psoriasis is characterised by keratinocyte hyperproli-
feration, by aberrant keratinocyte differentiation and by
cutaneous inflammation [10].
The high concentration of DPP-4 expressed on kerati-
nocytes and the fact that DPP-4 inhibition suppresses
keratinocyte proliferation in vitro, and restores partially
keratinocyte differentiation in vivo [30], support a poten-
tial role for DPP-4 inhibition therapy in the treatment of
psoriasis. Two cases of DPP-4 inhibitor therapy improving
psoriasis severity have been reported [8, 9]. One of these
two cases was a woman in our department with severe
psoriasis without diabetes who developed systemic B-cell
lymphoma [9]. Treatment with methotrexate and acitretin
were not tolerated or failed, and in the setting of the
patient’s concomitant malignancy, sitagliptin was com-
menced in preference to an immunosuppressive therapy.
After 8 weeks of oral sitagliptin treatment (100 mg once
daily) the psoriasis body surface area (BSA) involvement
decreased to less than 1 %.
DPP-4 inhibitors also prevent the degradation of insulin
secretagogues such as glucagon-like peptide-1 (GLP-1),
thereby ameliorating hyperglycaemia without causing
hypoglycaemia [31]. Because of these effects, DPP-4 inhib-
itors are licensed for the treatment of T2DM. Other inter-
ventions that increase GLP-1 receptor activation, such as
roux-en-Y gastric bypass surgery and GLP-1 analogue
therapy, can also improve psoriasis severity [32–34].
We have previously reported a significant improvement
in two patients with psoriasis and concomitant diabetes
treated with the GLP-1 analogue liraglutide [33]. In a sub-
sequent open study of seven patients with both psoriasis
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and type 2 diabetes we reported a significant reduction in
psoriasis severity and a significant improvement in quality
of life following treatment with liraglutide [35]. The me-
dian PASI decreased from 4.8 to 3.0 (p = 0.03) and median
DLQI from 6.0 to 2.0 (p = 0.03). The improvement in
patients treated with liraglutide was associated with an
increase in circulating invariant natural killer T (iNKT)
cells, innate T cells implicated in psoriasis pathogen-
esis, and a relative decrease in iNKT cell number in
psoriatic plaques.
Another study evaluated seven patients treated with ei-
ther exenatide or liraglutide for several months and found
a significant reduction in PASI of 2.8 (from 12.0 ± 5.9 to
9.2 ± 6.4; p = 0.04) and a slight reduction in epidermal
thickness (from 0.47 ± 0.12 to 0.40 ± 0.15 mm; p = 0.06).
The decrease in PASI was associated with a decrease in
Υδ-T cell number from 6.7 ± 4.5 to 2.7 ± 3.8 % (p = 0.05)
and IL-17 expression (p > 0.05), both of which are in-
volved in the pathogenesis of psoriasis [36]. These im-
provements in psoriasis are noted before weight loss
occurs [33, 34, 36] and are not associated with improved
glycaemic control [33–35].
A randomised clinical trial evaluated liraglutide in 20
obese glucose-tolerant patients with psoriasis [37]. After
8 weeks of treatment there was no significant difference
in the change in PASI between the liraglutide group and
the placebo group. There was a significant change in
PASI from baseline in the liraglutide group and not in
the placebo group. This was a small study (n = 20) and
the study duration of 8 weeks was short.
Dipeptidyl peptidase-4 is expressed as CD26 on T cells.
One hypothesis of sitagliptin’s potential effect in psor-
iasis treatment is that inhibition of DPP-4 may inhibit
T cell activation and improve psoriasis. While there is
evidence that sitagliptin decreases systemic inflamma-
tion, which may account for the reason it may be
beneficial in psoriasis, there is no evidence to suggest
that sitagliptin therapy is immunosuppressive. In one
cross-over study of 36 patients with T2DM treated
with sitagliptin or placebo, molecular markers of inflam-
mation were altered significantly in the sitagliptin group
[21]. Sitagliptin therapy (100 mg daily for 6 weeks) re-
duced serum concentrations of the inflammatory markers
CRP, IL-6, IL-18 and reduced concentrations of the
soluble cell adhesion proteins, intercellular adhesion
molecule 1 and E-selectin (molecules involved in the
development of atherosclerosis) in patients with T2DM.
The change in CRP was correlated inversely with a rise in
GLP-1 levels supporting a role for GLP-1 release, as well
as with improved glucose-insulin homeostasis, in the
improvement in systemic inflammatory and endothelial
markers. A reduction in CRP has been demonstrated in
other studies of patients with T2DM treated with sitaglip-
tin [16–22] although no change in CRP has also been
reported with sitagliptin therapy [38, 39]. One of the
studies demonstrating the anti-inflammatory action of
sitagliptin involved 22 obese patients with T2DM who
were allocated at random to receive sitagliptin 100 mg
daily or placebo for 12 weeks [22]. In this study peripheral
blood mononuclear cell expression of the inflammatory
molecules CD26 and TNFα decreased with sitagliptin
therapy as did serum concentrations of inflammatory
markers. Expression of CD26 decreased after a single dose
of sitagliptin and the authors suggested that sitagliptin
therapy, in addition to inhibiting the action of DPP-4, may
inhibit synthesis of DPP-4.
Sitagliptin monotherapy has demonstrated improvements
in measures of pancreatic β cell function (insulin secretion)
as determined by the homeostasis model assessment-β cell
function (HOMA-β) in the majority of studies evaluating
both sitagliptin as monotherapy [40–44] or sitagliptin as an
adjunctive therapy [45–49]. Improvements in insulin resist-
ance have shown varied results. The majority of studies
have shown improvements in insulin resistance when sita-
gliptin is used as an adjunctive treatment [45, 46, 48–50]
rather than as monotherapy [41–44, 51]. One study of sita-
gliptin monotherapy has demonstrated that insulin resist-
ance improved [40]. A meta-analysis of seven studies
comparing sitagliptin to metformin found that sitagliptin
was inferior to metformin in improving insulin resistance
(p = 0.003) [52]. The majority of these studies measured in-
sulin resistance using HOMA-IR, which correlates well
with the euglycaemic clamp, which is the ‘gold standard’ for
measuring insulin resistance [53]. Limitations associated
with the use of HOMA-IR include lack of consensus
regarding cut-off values and decreased reliability in lean
patients with T2DM (due to lower β cell function and
higher fasting glucose levels).
Sitagliptin treatment has not demonstrated immuno-
suppressive effects in healthy individuals. One study
evaluated sitagliptin 100 mg daily compared to placebo
for 28 days in healthy volunteers and measured immune
function [54]. There was no effect on cytokines mea-
sured including the immunosuppressive cytokine, trans-
forming growth factor β, on major lymphocyte subsets
and on numbers of regulatory T cells suggesting that
sitagliptin lacks immunomodulatory effects in healthy
patients. A non-sustained increase in CD26 levels in T
cells and increase in memory CD8+ T cells was observed.
It is possible that immune effects may differ in patients
with psoriasis, a chronic immune-mediated disease, and
this trial should provide further insight into the effects
of sitagliptin in psoriasis on immune function.
There are several other factors in support of sitagliptin
therapy being non-immunosuppressive. Clinical trial
data show no increase in the incidence of viral infections
or malignancy with sitagliptin therapy [55]. Twenty pa-
tients with human immunodeficiency virus (HIV) who
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did not have T2DM were treated with sitagliptin 100 mg
daily or placebo for 24 weeks and CD4+ T cell count
and plasma HIV RNA levels were not affected by sita-
gliptin treatment [56]. There was a reduction in stromal
derived factor-1α levels (required to protect T cells from
HIV entry) in the sitagliptin group but this did not affect
immune or virology status. These data support the lack
of a non-immunosuppressive effect with sitagliptin.
In addition to improvements in hyperglycaemia, sita-
gliptin treatment has demonstrated improvements in
other cardiovascular risk factors relevant to psoriasis
patients, although results are inconsistent. Sitagliptin ther-
apy has demonstrated improvements in blood pressure
measurements in some studies of patients with T2DM
[57–61] although other studies have shown no change in
blood pressure with sitagliptin treatment [38, 62, 63]. The
possible improvement in blood pressure may be related to
GLP-1-related natriuresis and vasodilation. Similarly, im-
provements in lipid parameters have been reported in
most [38, 50, 60, 64–66], but not all [39], studies of sita-
gliptin therapy.
Sitagliptin may also improve cardiac function. Pre-clinical
studies have supported the cardioprotective effect of DPP-4
inhibition therapy [67–70], which may be mediated by stro-
mal cell-derived factor-1 [70] associated with increased
stem cell mobilisation. Two clinical trials evaluating other
DPP-4 inhibitors, saxagliptin [71] and alogliptin [72], did
not, however, find a reduction in cardiovascular events in
patients with increased cardiovascular risk. The Trial to
Evaluate Cardiovascular Outcomes after Treatment with
Sitagliptin will be informative – this is an ongoing large
prospective study evaluating the cardiovascular outcomes
of patients with T2DM treated with sitagliptin [73].
Psoriasis is associated with multiple metabolic comorbidi-
ties including cardiovascular disease. Dipeptidyl peptidase-4
inhibitors, which reduce systemic inflammation and im-
prove metabolic health, may improve psoriasis severity and
may also provide an opportunity to treat, and prevent,
major comorbidities. This study is the first prospective
randomised clinical trial evaluating the potentially beneficial
effects of DPP-4 inhibition in patients with psoriasis
without diabetes.
Trial status
Recruitment began in November 2013 and is ongoing.
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